195 related articles for article (PubMed ID: 19997042)
1. Cytochrome b5 and NADH cytochrome b5 reductase: genotype-phenotype correlations for hydroxylamine reduction.
Sacco JC; Trepanier LA
Pharmacogenet Genomics; 2010 Jan; 20(1):26-37. PubMed ID: 19997042
[TBL] [Abstract][Full Text] [Related]
2. Individual variability in the detoxification of carcinogenic arylhydroxylamines in human breast.
Rhoads K; Sacco JC; Drescher N; Wong A; Trepanier LA
Toxicol Sci; 2011 Jun; 121(2):245-56. PubMed ID: 21447608
[TBL] [Abstract][Full Text] [Related]
3. Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes.
Clement B; Behrens D; Amschler J; Matschke K; Wolf S; Havemeyer A
Life Sci; 2005 May; 77(2):205-19. PubMed ID: 15862605
[TBL] [Abstract][Full Text] [Related]
4. Combined ascorbate and glutathione deficiency leads to decreased cytochrome b5 expression and impaired reduction of sulfamethoxazole hydroxylamine.
Bhusari S; Abouraya M; Padilla ML; Pinkerton ME; Drescher NJ; Sacco JC; Trepanier LA
Arch Toxicol; 2010 Aug; 84(8):597-607. PubMed ID: 20221587
[TBL] [Abstract][Full Text] [Related]
5. NADH cytochrome b5 reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans.
Kurian JR; Bajad SU; Miller JL; Chin NA; Trepanier LA
J Pharmacol Exp Ther; 2004 Dec; 311(3):1171-8. PubMed ID: 15302896
[TBL] [Abstract][Full Text] [Related]
6. Reductive detoxification of arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5.
Kurian JR; Chin NA; Longlais BJ; Hayes KL; Trepanier LA
Chem Res Toxicol; 2006 Oct; 19(10):1366-73. PubMed ID: 17040106
[TBL] [Abstract][Full Text] [Related]
7. Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC).
Ott G; Plitzko B; Krischkowski C; Reichmann D; Bittner F; Mendel RR; Kunze T; Clement B; Havemeyer A
Chem Res Toxicol; 2014 Oct; 27(10):1687-95. PubMed ID: 25170804
[TBL] [Abstract][Full Text] [Related]
8. N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.
Cribb AE; Spielberg SP; Griffin GP
Drug Metab Dispos; 1995 Mar; 23(3):406-14. PubMed ID: 7628308
[TBL] [Abstract][Full Text] [Related]
9. Discovery and characterization of a cytochrome b5 variant in humans with impaired hydroxylamine reduction capacity.
Kurian JR; Longlais BJ; Trepanier LA
Pharmacogenet Genomics; 2007 Aug; 17(8):597-603. PubMed ID: 17622936
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of polymorphisms in the sulfonamide detoxification genes CYB5A and CYB5R3 in dogs with sulfonamide hypersensitivity.
Funk-Keenan J; Sacco J; Wong YY; Rasmussen S; Motsinger-Reif A; Trepanier LA
J Vet Intern Med; 2012; 26(5):1126-33. PubMed ID: 22816446
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.
Sacco JC; Abouraya M; Motsinger-Reif A; Yale SH; McCarty CA; Trepanier LA
Pharmacogenet Genomics; 2012 Oct; 22(10):733-40. PubMed ID: 22850190
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of the naturally fused CS and cytochrome b
Benson DR; Lovell S; Mehzabeen N; Galeva N; Cooper A; Gao P; Battaile KP; Zhu H
Acta Crystallogr D Struct Biol; 2019 Jul; 75(Pt 7):628-638. PubMed ID: 31282472
[TBL] [Abstract][Full Text] [Related]
13. A single-nucleotide polymorphism in the canine cytochrome b
Reinhart JM; Ekena J; Cioffi AC; Trepanier LA
J Vet Pharmacol Ther; 2018 Jun; 41(3):402-408. PubMed ID: 29336038
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis.
Abouraya M; Sacco JC; Kahl BS; Trepanier LA
Br J Clin Pharmacol; 2011 Apr; 71(4):566-74. PubMed ID: 21204907
[TBL] [Abstract][Full Text] [Related]
15. P450 redox enzymes in the white rot fungus Phanerochaete chrysosporium: gene transcription, heterologous expression, and activity analysis on the purified proteins.
Subramanian V; Doddapaneni H; Syed K; Yadav JS
Curr Microbiol; 2010 Oct; 61(4):306-14. PubMed ID: 20221604
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous purification and characterization of cytochrome b5 reductase and cytochrome b5 from sheep liver.
Arinç E; Cakir D
Int J Biochem Cell Biol; 1999 Feb; 31(2):345-62. PubMed ID: 10216966
[TBL] [Abstract][Full Text] [Related]
17. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes.
Yamazaki H; Nakano M; Gillam EM; Bell LC; Guengerich FP; Shimada T
Biochem Pharmacol; 1996 Jul; 52(2):301-9. PubMed ID: 8694855
[TBL] [Abstract][Full Text] [Related]
18. Effect of lipopolysaccharide (LPS)-evoked host defense activation on hepatic microsomal formation and reduction of sulfamethoxazole hydroxylamine in the rat.
Cribb AE; McQuaid T; Renton KW
Biochem Pharmacol; 2001 Aug; 62(4):457-9. PubMed ID: 11448455
[TBL] [Abstract][Full Text] [Related]
19. Effect of divalent cations on NADH-dependent and NADPH-dependent cytochrome b5 reduction by hepatic microsomes.
Tamura M; Yoshida S; Tamura T; Saitoh T; Takeshita M
Arch Biochem Biophys; 1990 Aug; 280(2):313-9. PubMed ID: 2369123
[TBL] [Abstract][Full Text] [Related]
20. Role of carboxyl residues surrounding heme of human cytochrome b5 in the electrostatic interaction with NADH-cytochrome b5 reductase.
Kawano M; Shirabe K; Nagai T; Takeshita M
Biochem Biophys Res Commun; 1998 Apr; 245(3):666-9. PubMed ID: 9588172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
